#USA #Chicago #Cancer Treatment #Accent Therapeutics #ATX-559

Accent Therapeutics at ASCO 2025: Unveiling ATX-559

In an exciting development for cancer treatment, Accent Therapeutics has announced the presentation of a Trial in Progress poster for its groundbreaking Phase 1/2 study of ATX-559 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Scheduled to be held from May 30 to June 3 in Chicago, Illinois, this marks a significant moment for a clinical-stage biopharmaceutical company known for its innovative, targeted therapies aimed at fighting cancer.

ATX-559 is a first-in-class oral inhibitor specifically designed to target DHX9, a previously unexploited RNA and DNA/RNA helicase implicated in a variety of cancers that exhibit high replication stress. This unique approach underlines the potential of ATX-559 as a novel therapeutic option for patients suffering from advanced or metastatic breast cancer that may be BRCA-1 or BRCA-2 deficient, as well as those with microsatellite instability-high (MSI-H) and deficient mismatch repair (dMMR) solid tumors.

Significance of the Study

Dr. Jason Sager, Chief Medical Officer of Accent Therapeutics, expressed optimism regarding the clinical evaluation of ATX-559, stating, "As a novel inhibitor of DHX9, ATX-559 offers potential as a unique therapeutic approach for addressing cancers characterized by high replication stress." This sentiment is supported by the robust set of data that has emerged from the ongoing trials.

Beginning in late 2024, the open-label, dose-escalation and expansion study aims to evaluate multiple doses of ATX-559, with an emphasis on safety, tolerability, and preliminary anti-tumor efficacy according to established RECIST v1.1 criteria. The trial is actively enrolling participants, with focus groups specifically composed of patients battling BRCA-1 and/or BRCA-2-deficient metastatic breast cancer and other solid tumors identified as possessing significant replicative stress.

Presentation Details

The presentation of the Trial in Progress poster is slated for Monday, June 2, from 1:30 PM to 4:30 PM CDT in Hall A. Dr. Meredith Pelster will be presenting important findings related to ATX-559's potential therapeutic applications. The presentation, titled "Trial in Progress: First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients with Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers," will delve into the details of the study along with its abstract (Abstract Number TPS3181).

The Role of DHX9 in Cancer Treatment

DHX9 has emerged as a critical target due to its multifaceted role in managing replication stress, a significant issue in many tumors. The preclinical data has indicated that ATX-559 may demonstrate efficacy in treating tumors prevalent in large patient populations—including breast, colorectal, ovarian, and gastric cancers—that currently demand novel therapeutic strategies. Accent Therapeutics aims to utilize these findings to better understand the sensitivity of various tumor types to DHX9 inhibition.

The importance of ATX-559 cannot be overstated, as it symbolizes a leap forward in cancer therapeutics, promising a brighter future for patients with challenging diagnoses. The ongoing studies will determine its full potential and likely expand its use in combination therapies with other cancer treatments, thereby enhancing the overall effectiveness of cancer management strategies.

About Accent Therapeutics

Accent Therapeutics is at the forefront of developing a new class of precision cancer therapies. By focusing on significant intracellular dependencies, the company is committed to creating targeted therapies that can impact a broad range of cancers. Its lead compounds, ATX-559 and ATX-295 (a KIF18A inhibitor), are positioned for evaluation in Phase 1/2 trials to address critical therapeutics gaps in oncology. The ambition is clear: transform promising scientific concepts into life-altering treatments for patients fighting cancer.

For those interested in learning more, the Trial in Progress poster will be accessible on Accent Therapeutics' website following the conclusion of the meeting. This initiative reflects the ongoing commitment of Accent to push the boundaries of clinical research and cancer treatment, making significant contributions to the ever-evolving landscape of oncology.

For further insights and updates on their mission, please visit Accent Therapeutics Website or follow them on LinkedIn.